After the Food and Drug Administration approved Enhertu (fam-trastuzumab deruxtecan-nxki) for patients with HER2-positive solid tumors, an expert spoke with CURE® about the potential side effects. The ...

Side effects required dose reductions and interruptions in 22.8% and 55.5% of patients, respectively; side effects led to discontinuation for 15.2% of patients. Eight patients experienced side effects ...

The Food and Drug Administration (FDA) approved AstraZeneca’s Enhertu to treat HER2-low breast cancer. Enhertu is the first targeted treatment for this subtype of breast cancer. Following the ...

Though Enhertu’s targeted effect is intended to spare healthy tissue, ADCs still come with side effects. The most serious adverse effect reported in the clinical trial was interstitial lung ...

Enhertu is part of a newer type of cancer treatment called antibody-drug conjugates (ADC). ... Common side effects include nausea, fatigue and low blood counts. A rare but serious side effect is ...

Enhertu belongs to the class of therapies called antibody drug conjugates. ... platelets, and hemoglobin, all of which are already listed as known side effects of Enhertu.

ENHERTU was shown to be twice as effective as TDM1, the standard of care medication, ... "The side effects are minimal to none for a majority of the patients.

Enhertu is the second HER2-targeting ADC approved by the US Food and Drug Administration (FDA) after Roche’s Kadcyla (ado-trastuzumab etamine), which was approved in 2013 for HER2-positive (HER2 ...